Metagenomic analysis of the impact of nitrofurantoin treatment on the human faecal microbiotaOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers examined how nitrofurantoin, an antibiotic used for uncomplicated urinary tract infections, affects the faecal microbiota. They compared UTI patients on treatment with non-treated healthy controls.
How was it studied?
Serial stool samples were collected before treatment, within 48 hours of finishing treatment, and 28 days later. Samples underwent 16S rRNA pyrosequencing targeting the V3 to V5 region.
What did they find?
Actinobacteria rose by a mean of 19.6 percent right after treatment compared to baseline, then returned to near-baseline levels by day 28. This rise was driven almost entirely by Bifidobacterium, which made up 81.0 percent of the Actinobacteria increase.
Why it matters
No other significant microbiota disruption was observed beyond this transient Bifidobacterium increase. The authors conclude the findings support nitrofurantoin as a favorable option for UTI treatment relative to broader-spectrum antibiotics.